Opdualag to treat unresectable melanoma
Drug Name: Opdualag Active Ingredient: nivolumab and relatlimab-rmbw Indications: To treat unresectable or metastatic melanoma Approval Date: 3/18/2022 Company: Bristol-Myers Squibb Company Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761234s000lbl.pdf